Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BANCAP HC vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BANCAP HC contains hydrocodone, a mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, to reduce pain and fever.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of moderate to moderately severe pain,Off-label: cough suppression (hydrocodone component)
Mild to moderate pain,Fever
Each 5 m L contains hydrocodone bitartrate 5 mg and acetaminophen 500 mg. For moderate to moderately severe pain: 1 tablet (or 5 m L suspension) every 4 to 6 hours as needed; maximum single dose: 2 tablets (10 m L); maximum daily dose: 8 tablets (40 m L) due to acetaminophen limit.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life: 3.8 hours (range 3.3–4.4 h) for hydrocodone; clinical context: requires dosing every 4–6 hours to maintain analgesic effect, with potential accumulation in renal impairment.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Hydrocodone is metabolized by CYP2D6 and CYP3A4 to hydromorphone (active) and norhydrocodone; acetaminophen is primarily metabolized by glucuronidation and sulfation, with minor CYP2E1 oxidation to NAPQI.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal elimination of unchanged drug and metabolites: 90% (60% as glucuronide conjugates, 10% as unchanged drug, 5% as cysteine and mercapturic acid conjugates); biliary/fecal: 5%; the remainder as other metabolites. Renal clearance of hydrocodone is dose-dependent.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
20–30% bound to plasma proteins (primarily albumin).
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Vd: 3.5–4.0 L/kg; indicates extensive tissue distribution with high penetration into central nervous system.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: 70% (first-pass metabolism reduces bioavailability; range 60–80%).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
For GFR 30-50 m L/min: reduce dose to 75% of normal, extend interval to every 6 hours. For GFR <30 m L/min: avoid use; if necessary, use 50% of normal dose every 8 hours with careful monitoring.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: start at 50% of normal dose, titrate cautiously, maximum daily acetaminophen 2000 mg. Child-Pugh Class C: contraindicated.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Weight-based: hydrocodone 0.1-0.2 mg/kg/dose (max 10 mg/dose) every 4-6 hours as needed; acetaminophen 10-15 mg/kg/dose (max 75 mg/kg/day). For BANCAP HC 5-500: 0.1-0.2 m L/kg/dose (max 10 m L/dose) every 4-6 hours.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Initiate at 50% of adult dose (e.g., half tablet or 2.5 m L) every 6 hours; maximum daily acetaminophen 3000 mg; monitor renal function and avoid in frailty with GFR <30.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity (acetaminophen).
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Respiratory depression, drug interaction with CNS depressants, risk of hypotension, risk of serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, hepatotoxicity (acetaminophen), opioid-induced hyperalgesia, dependency/tolerance.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to hydrocodone or acetaminophen, significant respiratory depression, acute or severe bronchial asthma, gastrointestinal obstruction (including paralytic ileus), severe hepatic impairment (acetaminophen).
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid alcohol completely. Grapefruit juice may increase hydrocodone levels; caution advised. High-fat meals may delay absorption of hydrocodone, but no specific food restrictions.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
BANCAP HC contains hydrocodone and acetaminophen. Hydrocodone: Risk not fully established; first trimester: potential association with congenital malformations (limited data); second and third trimesters: prolonged use may cause neonatal opioid withdrawal syndrome and respiratory depression at delivery. Acetaminophen: Generally considered low risk at therapeutic doses; prolonged high-dose use may be associated with fetal adverse effects.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Hydrocodone: Excreted in breast milk; relative infant dose estimated <5% of maternal weight-adjusted dose; M/P ratio not well characterized. Monitor infant for sedation, respiratory depression, and poor feeding. Acetaminophen: Compatible with breastfeeding; minimal excretion.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No specific dose adjustments established for pregnancy. Increased clearance during pregnancy may require dose adjustments for pain relief; cautious use at lowest effective dose for shortest duration due to fetal risks.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
BANCAP HC is a combination of hydrocodone (an opioid) and acetaminophen. Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen dose should not exceed 4 g in adults. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; poor metabolizers may have reduced effect. Avoid concurrent use with other CNS depressants, including alcohol. Use with caution in patients with respiratory compromise, head injury, or biliary tract disorders.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take this medication exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Acetaminophen is also present in many over-the-counter products; check labels to avoid exceeding 4000 mg per day.,Do not consume alcohol while taking this medication; risk of liver damage and increased sedation.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Do not stop abruptly; withdrawal symptoms may occur. Consult your doctor for a tapering schedule.,Store securely away from children; accidental ingestion can be fatal.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BANCAP HC vs ACEPHEN, answered by our medical review team.
BANCAP HC is a Opioid Analgesic that works by BANCAP HC contains hydrocodone, a mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, to reduce pain and fever.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BANCAP HC and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BANCAP HC is: Each 5 m L contains hydrocodone bitartrate 5 mg and acetaminophen 500 mg. For moderate to moderately severe pain: 1 tablet (or 5 m L suspension) every 4 to 6 hours as needed; maximum single dose: 2 tablets (10 m L); maximum daily dose: 8 tablets (40 m L) due to acetaminophen limit.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BANCAP HC and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BANCAP HC is classified as Category C. BANCAP HC contains hydrocodone and acetaminophen. Hydrocodone: Risk not fully established; first trimester: potential association with congenital malformations (limited data); seco. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.